Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;19(1):19-28.
doi: 10.2217/fon-2022-0774. Epub 2023 Jan 18.

Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma

Frédérique St-Pierre  1 , Leo I Gordon  1
Affiliations
Review

Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma

Frédérique St-Pierre et al. Future Oncol. 2023 Jan.

Abstract

Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the approval of liso-cel in the third-line setting for R/R diffuse LBCL, primary mediastinal B-cell lymphoma, follicular lymphoma grade 3B and transformed lymphoma. The TRANSFORM and PILOT studies evaluated the use of liso-cel in the second-line treatment of R/R LBCL. This review details the structure and manufacturing process of liso-cel that make it distinct from other approved chimeric antigen receptor constructs, outlines results from landmark trials of liso-cel in LBCL and discusses liso-cel toxicity.

Keywords: CAR T-cell therapy; large B-cell lymphoma; lisocabtagene maraleucel.

Plain language summary

Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment for large B-cell lymphoma (LBCL). CAR T involves modifying a patient's immune cells (T cells, specifically), so that they can attack cancer cells and destroy them. Lisocabtagene maraleucel (liso-cel) is a type of CAR T-cell therapy that has been approved to treat patients with LBCL who have already received at least one line of treatment for their lymphoma. This article outlines the structure and manufacturing process of liso-cel and discusses how it differs from other approved CAR T-cell therapies. It also summarizes the clinical data for liso-cel in the treatment of LBCL, as well as its safety and expected side effects.

PubMed Disclaimer

LinkOut - more resources